Puma Biotechnology, Inc. Announces Alan H. Auerbach's Retirement from the Board
February 23, 2021 at 04:06 pm EST
Share
On February 17, 2021, following discussions with Alan H. Auerbach, Chief Executive Officer, President and Chairman of the Board of Directors of Puma Biotechnology, Inc., Hugh O'Dowd informed the Company that he does not intend to stand for re-election to the Company's Board of Directors when his current term expires at the Company's 2021 Annual Meeting of Stockholders.
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
PUMA BIOTECHNOLOGY, INC. 
